Roivant Sciences Ltd. Common Shares
IPOWe develop transformative medicines by building agile, focused companies called Vants.
Public · New York, United States · Founded 2014 · $200.0M raised
- Headquarters
- New York, New York
- Employees
- 201–500
- Founded
- 2014
- Business Model
- B2B
- Total Funding
- $200.0M
- Last Round
- $200.0M Growth EquityJan 2019
- Rounds
- 1
- Type
- Public
About
Roivant Sciences is a biopharmaceutical company founded in 2014 that accelerates medicine development by building nimble, entrepreneurially-structured subsidiaries called 'Vants', each focused on a specific disease area or therapeutic modality. Since 2019, Roivant's family of Vants has conducted 12 positive Phase 3 trials and achieved 8 FDA approvals, with one successful commercial launch: VTAMA (tapinarof) cream for plaque psoriasis in 2022. The company's model combines experienced drug development leadership with efficient capital allocation, allowing it to advance a broad and differentiated pipeline spanning dermatology, immunology, and other high-unmet-need areas at a fraction of the cost of traditional large pharma.
Summary
Roivant Sciences Ltd. Common Shares is a Biotech company based in New York, United States, founded in 2014. It has raised $200.0M in total across 1 round, most recently a $200.0M Growth Equity round in Jan 2019. Investors include NovaQuest and RTW Investments.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jul 2021
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...